Co-stimulatory molecule CD80 expression may correlate with anti-HCV treatment outcome

Gut

Volumn 60, Issue 8, 2011, Pages 1161-1162

  Sacchi, Alessandra ^a   Agrati, C ^a   D'Offizi, G ^a   Vlassi, Chrysoula ^a   Martini, F ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LETTER; MALE; MYELOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIGENS, CD80; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DENDRITIC CELLS; DRUG CARRIERS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; T-LYMPHOCYTES;

EID: 79960317087     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.210765     Document Type: Letter

References (4)

1. Tellinghuisen TL, Evans MJ, von Hahn T, et al. Studying hepatitis C virus: making the best of a bad virus. J Virol 2007;81:8853-67. (Pubitemid 47311431)
2. Mengshol JA, Golden-Mason L, Castelblanco N, et al; Virahep-C Study Group. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut 2009;58:964-73.
3. Sansom DM, Manzotti CN, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol 2003;24:313-18.
4. Rosen HR, Weston SJ, Im K, et al; Virahep-C Study Group. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007;46:350-8.